Anti-Infective Agents Clinical Trial
Official title:
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg (hereinafter as "Avelox") in treating secondary infection of chronic respiratory disease.It is a local prospective and observational study of patients who have received Avelox tablets for Laryngopharyngitis, Tonsillitis, Bronchitis acute, Pneumonia, Secondary infection in chronic respiratory diseases, Sinusitis. A total of 500 patients are to be enrolled and assessed during the period of treatment with Avelox.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03279120 -
Safety, PK, and PD Study of IVRs Releasing TFV and LNG
|
Phase 1 | |
Not yet recruiting |
NCT03793946 -
A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant
|
N/A | |
Completed |
NCT01073540 -
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
|
Phase 1 | |
Completed |
NCT01073553 -
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
|
Phase 1 | |
Terminated |
NCT04489420 -
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
|
Phase 1 | |
Completed |
NCT01244698 -
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
|
Phase 4 | |
Completed |
NCT01231763 -
Acceptability Study of Vaginal Films for HIV Prevention
|
N/A | |
Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT01105208 -
Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
|
Phase 1 | |
Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
Completed |
NCT02046512 -
Probiotics to Promote Intestinal Health
|
Phase 4 | |
Completed |
NCT04210713 -
Neuroimmune Dysfunction in Alcohol Use Disorder
|
Phase 1 | |
Completed |
NCT04448665 -
Compliance of Initial Empiric Antimicrobial Therapy
|
||
Completed |
NCT05979207 -
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
|
Phase 1 | |
Recruiting |
NCT02242968 -
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
|